Dr. Scott C. Weaver (born 1957)
ASSOCIATIONS
..
Zika virus epidemic (2015-2016) ( ... )
Saved Wikipedia (Sep 29, 2021) - "Scott C. Weaver"
https://en.wikipedia.org/wiki/Scott_C._Weaver
2021-09-29-wikipedia-org-scott-c-weaver.pdf
Scott C. Weaver is an American virologist who is the research director of Galveston National Laboratory.[1][2][3]
References
Scholia has an author profile for Scott C. Weaver.
^ Cook, James (18 July 2018). "Zika vaccine 'could be 10 years away'" – via www.bbc.co.uk.
^ "Zika Virus, a Mosquito-Borne Infection, May Threaten Brazil's Newborns". nytimes.com.
^ "Leadership". Galveston National Laboratory. Retrieved 29 March 2019.
External links
2021 (Sep 29) - Profile on MD.RCM.UPR.EDU : "Scott C. Weaver, PhD"
https://md.rcm.upr.edu/bkamemorial/scott-c-weaver-phd/
2021-09-29-md-rcm-upr-edu-bkaemorial/scott-c-weaver-phd.pdf
2021-09-29-md-rcm-upr-edu-bkaemorial/scott-c-weaver-phd-img-1.jpg
Dr. Scott C. Weaver is Director of the Institute for Human Infections & Immunity (IHII), Scientific Director of the Galveston National Laboratory, and Chair of the Department of Microbiology & Immunology at the University of Texas Medical Branch (UTMB). He earned his BS degree from the College of William and Mary in 1979, his MS degree in entomology from Cornell University in 1982, and his PhD degree in virology from the University of California, San Diego in 1993. Following a postdoctoral fellowship in the Department of Epidemiology and Public Health at Yale University School of Medicine, he joined the UTMB faculty in 1994. He has served as Director of the IHII since 2010. Formerly the Vice Chair for Research in the Department of Pathology, Dr. Weaver currently holds the John Sealy Distinguished University Chair in Human Infections and Immunity. He is also a member of the Sealy Center for Vaccine Development, the Center for Biodefense and Emerging Infectious Diseases, the Institute for Translational Science, and a Core Member of the Sealy Center for Structural Biology. Dr. Weaver is an internationally recognized virologist and vector biologist, as evidenced by more than 250 publications in prestigious scientific journals and many invited presentations at international meetings. He is the recipient of numerous NIH, DTRA, DHS, CDC, and DARPA grants, and a W.M. Keck Foundation award. He has received many awards from and holds leadership positions in a number of national and international scientific societies and professional organizations. Dr. Weaver’s high standing in the scientific community is also indicated by his service on national and international committees and study sections, as well as many editorial responsibilities. He has served as associate editor for PLoS Neglected Tropical Diseases and PLoS Pathogens, as editor for Archives of Virology, as section editor (virology, vector biology) for the American Journal of Tropical Medicine and Hygiene, and as an editorial board member of the Journal of Virology and Current Opinion in Virology, among others. In addition, he holds five patents in vaccine development. Dr. Weaver teaches extensively and is the Leon Bromberg Professor of Excellence in Teaching.
EVIDENCE TIMELINE
2015 (Sep 29) - START FEARING ZIKA !!!!!!!
Full newspaper page : [HN01PM][GDrive] / Foreshadowing of Zika virus epidemic (2015-2016)
Mentioned :
[Dr. Scott C. Weaver (born 1957)], director of the Institute for Human Infections and Immunity at Univ. of Texas Medical
Dennis Tappe
2016 (May 03) - "
https://gvn.org/award-scott-weaver/
2016-05-03-globalvirusnetwork-award-scott-weaver-first-robert-c-gallo-award.pdf
2016-05-03-globalvirusnetwork-award-scott-weaver-first-robert-c-gallo-award-img-1.jpg
May 3, 2016/in News, Press Release /by Communications
Global Virus Network (GVN) Presents Mosquito-Borne Virus Expert for Scientific Excellence
The Award was presented during a meeting organized by Emory University and co-sponsored by the GVN on the Zika virus
May 2, 2016, Atlanta, GA: The Global Virus Network (GVN), representing 35 Centers of Excellence and 5 Affiliates in 26 countries, and comprising foremost experts in every class of virus causing disease in humans, today announced Scott Weaver, MS, PhD, as the first recipient of the GVN Robert C. Gallo Award for Scientific Excellence. Dr. Weaver is Chair of GVN’s Chikungunya and Zika Task Forces as well as director of the University of Texas Medical Branch’s Institute for Human Infections and Immunity and scientific director of the Galveston National Laboratory, a GVN Center of Excellence. The Award was presented by José Esparza, MD, PhD, president of the GVN and Raymond Schinazi, PhD, Hon Dsc, member of the GVN Board of Advisors and Zika Task Force and the Frances Winship Walters Professor at Emory University. The honor was bestowed during a scientific meeting entitled, “Bridging the Sciences: Zika Virus,” organized by Emory University and co-sponsored by GVN in Atlanta, Georgia May 1-3, 2016.
L to R: Raymond Schinazi, PhD, Hon Dsc, Emory University; Scott Weaver, MS, PhD, Galveston National Laboratory; José Esparza, MD, PhD, president of the GVN; Mario Stevenson, PhD, University of Miami Miller School of Medicine; and, Suzane K Ono-Nita, MD, PhD, University of São Paulo
“It was unanimous when deciding who should receive the inaugural Award, and it is my great pleasure that Dr. Scott Weaver will be the first honoree,” said Dr. Robert C. Gallo, Co-founder and International Scientific Advisor of the Global Virus Network (GVN), The Homer and Martha Gudelsky Distinguished Professor in Medicine, co-founder and director of the Institute of Human Virology at the University of Maryland School of Medicine, a GVN Center of Excellence. “Dr. Weaver is not only a leader in the GVN, but an exceptional public health virologist who is most deserving of this recognition. A warm congratulations to Dr. Weaver.”
[one_whole]Scott Weaver, MS, PhD Biography
Scott Weaver, MS, PhD, is a virologist and vector biologist who advances our understanding of arthropod-borne viruses (arboviruses) and their transmission by mosquitoes, and develops vaccines to control the diseases that they cause. As a faculty member since 1994 at the University of Texas Medical Branch (UTMB) in Galveston, he has developed an internationally recognized research program encompassing the ecology and epidemiology of enzootic arbovirus transmission cycles, virus-mosquito interactions, and emergence mechanisms of epidemic strains. Dr Weaver utilizes his broad training to develop interdisciplinary approaches that have had major impacts on our understanding of arboviral disease emergence. These include Venezuelan equine encephalitis, for which the international research groups he has led determined the ecological and evolutionary sources as well as mechanisms of epidemic strain emergence. Dr Weaver’s recent studies have focused on chikungunya virus, its history of emergence from wildlife African cycles, mosquito-adaptive evolution, and its viral genetic constraints, as well as Zika virus, which arrived in the Americas and is causing a major epidemic associated with congenital microcephaly and Guillain Barré syndrome. His research on tropical arboviral diseases has included major field studies in Venezuela, Colombia, Peru, Mexico, Panama, Senegal, and Kenya. Dr Weaver has also developed promising new vaccines for several of these arboviral diseases. The chikungunya vaccine developed in his laboratory, licensed to Takeda Pharmaceuticals and patented in 19 countries, is in late preclinical evaluation.
Dr Weaver’s research has led to over 260 peer-reviewed publications in scientific journals, and over 70 reviews and book chapters. He has mentored 18 PhD students as well as 23 postdoctoral fellows, and many have gone on into prominent, independent scientific positions in government, academia, and industry. Dr Weaver’s research and educational contributions have been recognized with many local and international awards. In 2014 he received the Walter Reed medal, awarded every three years by the American Society of Tropical Medicine and Hygiene for distinguished career accomplishments in tropical medicine research. His many leadership positions include his current role as chair of the Global Virus Network’s Chikungunya and Zika Task Forces. He also serves as an editor for several major tropical medicine and microbiology journals. At UTMB, Dr Weaver leads the Institute for Human Infections and Immunity (IHII), which coordinates infectious disease research as the administrative home of the Galveston National Laboratory (one of two NIH-funded national biocontainment facilities); the Sealy Center for Vaccine Development; the Center for Biodefense and Emerging Infectious Diseases; and the Center for Tropical Diseases. He is also scientific director of the Galveston National Laboratory, and interim chair of the Department of Microbiology and Immunology.
Directory info : Scott C Weaver in the U.S., Public Records Index, 1950-1993, Volume 1
Name : Scott C Weaver
Birth Date : 9 Jul 1957
Residence Date : 1993
Address : 9152 Regents Rd Apt D / LA Jolla, CA / Postal Code : 92037-1450
Second Residence Date : 1993
Second Address : 7689 Palmilla Dr / San Diego, CA / 92122-4712
Scott C. Weaver, MS, PhD
https://microbiology.utmb.edu/faculty/scott-weaver-phd
John Sealy Distinguished University Chair in Human Infections and Immunity
Chair, Department of Microbiology & Immunology
Director, Institute for Human Infections & Immunity
Scientific Director, Galveston National Laboratory
Professor, Microbiology & Immunology and Pathology
Phone: (409) 266-6500
Mail Route: 0610
Office: Galveston National Laboratory (GNL) 6.200D
Email: sweaver@utmb.edu
EDUCATION
Post-doctoral Fellowship
Yale University School of Medicine
1994
New Haven, CT
PhD, Molecular Biology and Virology
University of California, San Diego
1993
La Jolla, CA
MS, Medical Entomology
Cornell University
1982
Ithaca, NY
BS, Biology and Music
The College of William and Mary
1979
Williamsburg, VA
RESEARCH INTERESTS
Ecology, epidemiology, evolution, and pathogenesis of arboviral diseases; vaccine development
CURRENT RESEARCH
Dr. Weaver’s research focuses on the ecology, evolution, epidemiology and pathogenesis of arboviral diseases, arbovirus‐mosquito vector interactions, and vaccine development for arboviral disease prevention. Current projects include emergence mechanisms, pathogenesis and vector transmission of Zika and chikungunya viruses. His lab is also developing a newly discovered mosquito‐specific alphavirus, Eilat virus, as a vaccine and diagnostic antigen platform, as well as developing vesiculoviruses as new vaccine vectors. He also leads the CDC‐funded Western Gulf Center of Excellence in Vector‐borne Diseases, involving eight academic and multiple public health institutions in Texas, and the World Reference Center for Emerging Viruses and Arboviruses.
PUBLICATIONS